KEAP1 and neoplasm: About 15%-30% of HNSCC patients have KEAP1 dysfunction mutations, resulting in sustained NRF2 pathway activation. In HNSCC, high NRF2 activity promotes tumor resistance by enhancing antioxidant defense and reducing cupr-induced cell death.